Morepen Laboratories Ltd

Morepen Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Morepen Laboratories Ltd

₹ 55.7 3.82%
28 Jun - close price
morepen.com BSE: 500288 NSE: MOREPENLAB
About

Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products.[1]

Key Points

Leadership in Anti-Asthmatic drug
The company is world leader in Loratadine (140 MT) and has achieved the leadership position of being one of the largest suppliers of anti-asthmatic drug, Montelukast Sodium (85 MT). It is a prominent player in commercial production of drugs Atorvastatin calcium (120 MT), Rosuvastatin calcium of anti-hypercholesterolemic series, Fexofenadine Hydrochloride of antihistamine series, Olmesartan of anti-hypertensive series & their intermediates. [1] [2]

Website BSE NSE
  • Market Cap ₹ 2,848 Cr.
  • Current Price ₹ 55.7
  • High / Low ₹ 59.8 / 28.5
  • Stock P/E 25.7
  • Book Value ₹ 17.4
  • Dividend Yield 0.00 %
  • ROCE 17.7 %
  • ROE 13.3 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 12.9% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
264 365 369 372 342 274 383 345 337 369 381 395 393
236 323 333 342 323 261 356 323 321 344 352 344 336
Operating Profit 28 43 37 30 19 14 27 21 15 25 30 51 56
OPM % 10% 12% 10% 8% 6% 5% 7% 6% 4% 7% 8% 13% 14%
4 2 3 3 3 1 1 1 3 2 3 4 4
Interest -0 0 -9 1 1 0 0 1 1 0 0 2 1
Depreciation 6 5 6 5 5 4 4 5 5 5 5 6 7
Profit before tax 25 39 43 27 17 10 23 18 13 22 27 47 53
Tax % -0% 20% 20% 21% 14% 28% 28% 28% 21% 27% 27% 25% 24%
25 31 34 22 14 7 17 13 10 16 20 35 40
EPS in Rs 0.56 0.69 0.77 0.48 0.30 0.14 0.32 0.25 0.20 0.31 0.39 0.69 0.78
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
303 336 370 452 548 561 717 792 1,112 1,449 1,339 1,538
274 290 324 388 487 501 652 728 1,000 1,320 1,262 1,376
Operating Profit 29 46 47 64 60 60 65 64 112 129 77 162
OPM % 10% 14% 13% 14% 11% 11% 9% 8% 10% 9% 6% 11%
6 4 1 -3 4 4 4 9 12 10 6 13
Interest 12 10 9 10 7 4 2 2 2 -7 2 4
Depreciation 46 46 39 35 34 33 38 34 28 21 18 22
Profit before tax -23 -6 1 16 23 26 29 37 94 126 63 149
Tax % -0% -0% 19% -1% -0% -0% -0% 14% -0% 20% 27% 26%
-23 -6 1 16 23 26 29 32 94 101 46 111
EPS in Rs -0.50 -0.14 0.01 0.35 0.52 0.58 0.64 0.72 2.10 2.11 0.90 2.17
Dividend Payout % -0% -0% -0% -0% -0% -0% -0% -0% -0% -0% -0% -0%
Compounded Sales Growth
10 Years: 16%
5 Years: 16%
3 Years: 11%
TTM: 15%
Compounded Profit Growth
10 Years: 30%
5 Years: 31%
3 Years: 6%
TTM: 140%
Stock Price CAGR
10 Years: 26%
5 Years: 24%
3 Years: -4%
1 Year: 84%
Return on Equity
10 Years: 13%
5 Years: 15%
3 Years: 13%
Last Year: 13%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 90 90 90 90 90 90 90 90 90 96 102 102
Reserves 121 115 103 119 134 161 188 217 311 476 678 787
Preference Capital 120 120 120 120 -0 -0 -0 -0 -0 -0 -0
111 89 81 67 168 134 139 142 17 19 25 28
220 214 226 259 155 206 203 212 429 443 300 362
Total Liabilities 542 508 500 535 548 591 619 662 848 1,033 1,106 1,279
331 289 244 216 191 182 153 135 144 156 171 217
CWIP -0 -0 -0 -0 -0 -0 -0 -0 2 14 17 24
Investments 122 118 118 118 118 118 118 119 119 118 118 126
89 100 138 201 239 291 349 408 583 745 800 912
Total Assets 542 508 500 535 548 591 619 662 848 1,033 1,106 1,279

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
33 33 51 50 49 61 15 11 49 -69 -102 77
-3 -1 -30 -27 -15 -24 -10 -12 -69 -23 -36 -84
-30 -29 -20 -28 -31 -38 -0 5 47 66 144 0
Net Cash Flow 1 3 1 -5 3 -1 4 3 28 -25 6 -6

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 44 44 48 65 55 72 62 56 51 56 70 75
Inventory Days 70 60 56 53 68 79 71 93 84 95 85 85
Days Payable 105 122 124 140 126 176 123 111 95 80 86 103
Cash Conversion Cycle 9 -18 -21 -22 -3 -25 10 38 40 71 69 57
Working Capital Days -30 -16 -16 -6 -91 -66 -31 -4 22 62 111 110
ROCE % -3% 0% 2% 8% 8% 8% 8% 9% 22% 23% 9%

Shareholding Pattern

Numbers in percentages

12 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
34.54% 34.54% 34.54% 38.38% 36.74% 38.22% 38.22% 38.22% 38.22% 38.22% 38.22% 38.22%
0.68% 0.86% 0.91% 0.96% 0.95% 1.15% 0.89% 0.96% 1.00% 1.29% 2.11% 1.85%
2.05% 1.26% 1.16% 1.07% 4.08% 3.98% 3.74% 2.93% 2.32% 2.27% 2.21% 2.15%
0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
62.73% 63.34% 63.39% 59.59% 58.24% 56.63% 57.15% 57.88% 58.45% 58.20% 57.46% 57.76%
No. of Shareholders 2,30,6112,44,9242,55,1552,61,4372,87,1152,90,3673,06,0303,06,1503,01,8323,04,0013,04,2893,36,019

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls